Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Adomi M, Ray A. Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease. Aliment Pharmacol Ther 2022;55:1069. [PMID: 35362122 DOI: 10.1111/apt.16871] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]

For:	Adomi M, Ray A. Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease. Aliment Pharmacol Ther 2022;55:1069. [PMID: 35362122 DOI: 10.1111/apt.16871] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]

Number

Cited by Other Article(s)

Selinger CP, Lenti MV, De Silvestri A. Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply. Aliment Pharmacol Ther 2022;55:1070-1071. [PMID: 35362123 DOI: 10.1111/apt.16896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]